French Tech 120 - Promotion 2023
Le French Tech 120 est un programme d’accompagnement de l’État dédié aux 120 start-up françaises les plus performantes, en capacité de devenir leaders de rang international. Elles bénéficient pendant un an d’un accompagnement en lien avec leurs enjeux de développement en France et à l’international.
French Tech 120
2021
![DNA Script DNA Script](https://beta.motherbase.ai/media/logo/74211.jpeg)
DNA Script
Transforming how molecular biology translates to human health, personalized medicine and synthetic biology DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAXTM️, the world’s … [voir plus]
![Enterome Enterome](https://beta.motherbase.ai/media/logo/102834_SRSw00f.jpeg)
Enterome
Delivering the promise of immunotherapy Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological … [voir plus]
![Igyxos Igyxos](https://beta.motherbase.ai/media/logo/91575.jpeg)
Igyxos
Igyxos develop more effective/efficient infertility treatment for patients Igyxos is a biotechnology company based out of CENTRE INRAe VAL DE LOIRE SITE DE TOURS, NOUZILLY, France. [voir plus]
![ImCheck Therapeutics ImCheck Therapeutics](https://beta.motherbase.ai/media/logo/86444.jpeg)
ImCheck Therapeutics
Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic ImCheck Therapeutics is designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. As demonstrated by lead clinical-stage program ICT01, which has a mechanism of action to simultaneously modulate innate and adaptive immunity, … [voir plus]
![Inotrem Inotrem](https://beta.motherbase.ai/media/logo/91567.jpeg)
Inotrem
Control innate immunity Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced … [voir plus]
![TISSIUM TISSIUM](https://beta.motherbase.ai/media/logo/91564.jpeg)
TISSIUM
Biomorphic Programmable Polymers TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, … [voir plus]
![Dynacure Dynacure](https://beta.motherbase.ai/media/logo/86519.jpeg)
Dynacure
Dynacure is a clinical-stage company focused on developing novel therapies for rare diseases. Dynacure is a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Dynacure is developing DYN101, an investigational antisense product candidate … [voir plus]
![ENYO Pharma ENYO Pharma](https://beta.motherbase.ai/media/logo/7217.jpeg)
ENYO Pharma
Développer des thérapies pour les maladies rénales chroniques ENYO Pharma est une société biopharmaceutique au stade clinique. Notre mission est de développer des molécules aux propriétés fibrolytiques et anti-inflammatoires pour améliorer la qualité de vie des patients souffrant d’insuffisance rénale. Vonafexor est actuellement en Phase 2 pour le traitement du … [voir plus]
![EYEVENSYS EYEVENSYS](https://beta.motherbase.ai/media/logo/120432.jpeg)
EYEVENSYS
We create ophthalmic therapeutic bio factories to sustainably treat major eye diseases. Eyevensys is a clinical stage, private, biotechnology company developing its innovative EyeCET platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic disease. EyeCET stands for the eye ciliary muscle electro-transfection … [voir plus]